Prognosis
Pfizer, BioNTech Shot May Defeat New Variants, Study Shows
- Study looked at mutation common to U.K., South Africa strains
- The early data hasn’t yet been subjected to peer review
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
Pfizer Inc. and BioNTech SE’s Covid-19 vaccine may protect against the new fast-spreading variants of the coronavirus that have emerged in the U.K. and South Africa, according to a study.